Key Highlights
- The FDA set an October 17, 2026 PDUFA goal date for Viatris (NASDAQ:VTRS) supplemental application for MR-141, phentolamine ophthalmic solution 0.75%, for presbyopia, per the company release of February 25, 2026.
- The filing would expand the label of Ryzumvi, which is currently approved only to reverse pharmacologically induced pupil dilation caused by adrenergic or parasympatholytic agents.
- The company said Phase 3 trials VEGA-2 and VEGA-3 both met their primary and all key secondary endpoints, with no treatment-related serious adverse events reported in the release.
- Viatris (NASDAQ:VTRS) holds exclusive US commercialization rights under a global licensing agreement with Opus Genetics, and the release did not disclose milestone or Royalty terms.
What Is Being Decided
Viatris (NASDAQ:VTRS) announced on February 25, 2026 that the FDA accepted its supplemental new drug application for MR-141, phentolamine ophthalmic solution 0.75%, as a treatment for presbyopia, the age-related loss of near focusing. A supplemental application asks the agency to broaden an existing approval. The target action date under the Prescription Drug User Fee Act, known as the PDUFA date, is October 17, 2026. The product is already sold as Ryzumvi for reversing pharmacologically induced pupil dilation. Philippe Martin, chief Research and Development officer at Viatris, said the company is confident in the strength of the clinical data supporting the submission. Viatris holds exclusive US commercialization rights through a global licensing agreement.
The Evidence and the Market
The company said VEGA-2 and VEGA-3, the pivotal Phase 3 trials, met their primary and all key secondary endpoints with no treatment-related serious adverse events. The release did not give patient numbers or the share of patients who gained lines of near vision, so the size of the benefit cannot be judged here. A reported calendar summary said Viatris estimates that presbyopia affects about 90% of US adults over 45, a figure not verified against a company source. For Ryzumvi, the common adverse reactions were instillation site discomfort in 16% of patients, conjunctival hyperemia in 12% and dysgeusia, a taste change, in 6%. A new use would target a far larger patient group than the current label.
Risks and What to Watch
An FDA decision date is a target, not a promise. The agency can approve, issue a complete response letter or extend the review, and companies do not always announce delays in advance. If approved, Viatris (NASDAQ:VTRS) must still build Demand against reading glasses and other presbyopia options, and payers may not cover a cosmetic-leaning use. Safety in a larger population could differ from the trials, and label limits could narrow the market. Watch for an approval announcement after the October 17, 2026 date, label wording, pricing and commercial launch plans, plus any sign of an extended review. A calendar summary also reported Viatris shares were up about 41% year to date, a reported figure that was not verified, so no price view is taken here. This is not Investment advice.
Where Things Stand
If the FDA approves MR-141 on or around October 17, 2026, Viatris (NASDAQ:VTRS) could extend Ryzumvi from a niche Reversal agent to a presbyopia treatment aimed at a much larger group of adults, with exclusive US commercialization rights. The company reports positive Phase 3 results, but the release gave no detailed efficacy numbers. The balance of evidence is encouraging and unproven until the label is known. The next catalyst is the FDA action itself.






Please wait processing your request...